Researchers at the University of Pennsylvania and Cincinnati Children’s have developed a pioneering mRNA vaccine aiming to prevent severe allergic reactions to common foods and seasonal allergens. Published in the Journal of Clinical Investigation, this study represents a transformative approach to allergy immunotherapy using genetic technology to reprogram immune responses and prevent dangerous hypersensitivity. This innovation holds potential to dramatically shift allergy prevention and treatment paradigms.